# 3H Health Investment

> 3H Health Investment is a VC fund backing Health Care and Pharmaceutical. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cyberport, Hong Kong
- Total investments: 25
- Last investment: Feb 2026
- Lead investor: 20%
- Last fund: Nov 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/3h-health-investment-management
- Website: http://www.3hhinvestment.com/

3H Health Investment is a dedicated healthcare private equity fund focusing on China. We believe that the combination of our proactive and creative investment approach, deep understanding of the China market, extensive industry network, and excellent fund management experience provides us with an edge in identifying and creating value in investmentopportunities.

## Contacts

5 contacts available for 3H Health Investment. Shizune tracks 2 team members at 3H Health Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/3h-health-investment?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 36% |
| Pharmaceutical | 7 | 28% |
| Biopharma | 6 | 24% |
| Biotechnology | 6 | 24% |
| Medical | 5 | 20% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 40% |
| Series A | 5 | 20% |
| Series C | 4 | 16% |
| Series D | 2 | 8% |
| Private Equity | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 17 | 68% |
| United States | 2 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Minchuan Wang | Partner | 7 | https://shizune.co/investors/profile/minchuan-wang |
| Sheng Li | Founding Managing Partner | 2 | https://shizune.co/investors/profile/sheng-li-aa56 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M | Series D | Feb 05, 2026 |  |
| Timberlyne Therapeutics | Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs. | $180M | Series A | Jan 09, 2025 |  |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $120M | Series C | Dec 11, 2024 |  |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $46M | Series B | Oct 19, 2023 |  |
| Chamlion | Chamlion provides end-to-end digital dentistry solutions based on 3D printing technology. | $34.3M | Series B | Apr 19, 2023 |  |
| Chenglian Technology | Chamlion 3D is a national high-tech enterprise incubated and established by the Additive Manufacturing Institute of Nanjing University of Aeronautics and Astronautics. Digital solutions for dental 3D printing, leading the digital transformation and upgrading of the industry. Chenglian Technology is deeply engaged in the field of dentistry, with itsin-depth understanding of the industry and rich product development. | $34.3M | Series B | Apr 18, 2023 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $29.1M | Series C | Apr 12, 2023 |  |
| Yuanyin Bio | Yuanyin Bio focuses on the research and application of circular RNA technology in the field of innovative drugs and innovative therapies. | $42M | Series A | Jun 20, 2022 |  |
| Tripod Preclinical Research Laboratories | Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), foodadditives, biologics，pesticides，veterinary drugs, and new cosmetics. | $156.3M | Venture - Series Unknown | Nov 05, 2021 |  |
| Edge Medical Robotics | Edge Medical Robotics, Inc. was founded in Longgang, Shenzhen, China on May 4, 2017. It is committed to researching and promoting most advanced smart equipment in the world，polishing the ultimate product with the spirit of pursuing excellence and fineness, improving surgical safety and treatment efficacy, and contributing to uprising the level ofsocial health. | $200M | Series C | Nov 05, 2021 |  |

10 of 25 investments shown.

## Co-investors
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 7 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 7 deals together
- [CD Capital](https://shizune.co/investors/profile/cd-capital) — VC Fund, 6 deals together
- [Quan Capital](https://shizune.co/investors/profile/quan-capital) — VC Fund, 5 deals together
- [Huagai Capital](https://shizune.co/investors/profile/huagai-capital) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does 3H Health Investment invest in?

3H Health Investment invests primarily in Health Care, Pharmaceutical and Biopharma startups, most often at Series B and Series A stage. Most of the 25 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact 3H Health Investment?

Public channels for 3H Health Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 3H Health Investment?

The team at 3H Health Investment includes Minchuan Wang (Partner) and Sheng Li (Founding Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co